"Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) Resistant/Intolerant to Two or Three Approved Tyrosine Kinase Inhibitors (TKIs)(1)(")

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib.

Patients taking imatinib (Gleevec) for CML, or chronic myelogenous leukemia, and in remission after two years of treatment, have a mortality rate similar to that of the general population according to a study published online [date] in the Journal of the National Cancer Institute.

Omacetaxine launches different attack on CML that is impervious to other therapies.

NEW ORLEANS, Dec. 5 /PRNewswire-USNewswire/ -- Leukemia and myeloproliferative disorders are serious and often deadly blood cancers.